Royal Bank of Canada’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.4M | Buy |
1,486,049
+1,404,922
| +1,732% | +$9.62M | ﹤0.01% | 1819 |
|
|
2025
Q4 | $162K | Sell |
81,127
-799,251
| -91% | -$1.81M | ﹤0.01% | 4907 |
|
|
2025
Q3 | $2.17M | Sell |
880,378
-344,682
| -28% | -$888K | ﹤0.01% | 3341 |
|
|
2025
Q2 | $3.23M | Buy |
1,225,060
+1,167,987
| +2,046% | +$3.14M | ﹤0.01% | 2924 |
|
|
2025
Q1 | $172K | Sell |
57,073
-46,684
| -45% | -$141K | ﹤0.01% | 4817 |
|
|
2024
Q4 | $266K | Sell |
103,757
-23,779
| -19% | -$99.1K | ﹤0.01% | 4578 |
|
|
2024
Q3 | $475K | Sell |
127,536
-342,658
| -73% | -$1.59M | ﹤0.01% | 4139 |
|
|
2024
Q2 | $2.97M | Buy |
470,194
+416,596
| +777% | +$2.75M | ﹤0.01% | 2591 |
|
|
2024
Q1 | $288K | Sell |
53,598
-31,930
| -37% | -$145K | ﹤0.01% | 4392 |
|
|
2023
Q4 | $429K | Buy |
85,528
+1,009
| +1% | +$3.17K | ﹤0.01% | 4404 |
|
|
2023
Q3 | $143K | Buy |
84,519
+34,531
| +69% | +$69.3K | ﹤0.01% | 5104 |
|
|
2023
Q2 | $138K | Buy |
49,988
+4,552
| +10% | +$12.9K | ﹤0.01% | 5072 |
|
|
2023
Q1 | $82K | Sell |
45,436
-140,115
| -76% | -$436K | ﹤0.01% | 5331 |
|
|
2022
Q4 | $941K | Buy |
185,551
+143,844
| +345% | +$790K | ﹤0.01% | 3549 |
|
|
2022
Q3 | $208K | Sell |
41,707
-6,480
| -13% | -$29.5K | ﹤0.01% | 4742 |
|
|
2022
Q2 | $180K | Sell |
48,187
-6,506
| -12% | -$26.1K | ﹤0.01% | 4882 |
|
|
2022
Q1 | $308K | Sell |
54,693
-14,293
| -21% | -$87.7K | ﹤0.01% | 4688 |
|
|
2021
Q4 | $419K | Buy |
68,986
+18,096
| +36% | +$136K | ﹤0.01% | 4629 |
|
|
2021
Q3 | $496K | Buy |
50,890
+4,855
| +11% | +$53.4K | ﹤0.01% | 4366 |
|
|
2021
Q2 | $658K | Buy |
46,035
+4,653
| +11% | +$76.9K | ﹤0.01% | 4023 |
|
|
2021
Q1 | $983K | Buy |
41,382
+4,238
| +11% | +$110K | ﹤0.01% | 3607 |
|
|
2020
Q4 | $495K | Buy |
37,144
+17,830
| +92% | +$172K | ﹤0.01% | 4146 |
|
|
2020
Q3 | $134K | Buy |
19,314
+1,249
| +7% | +$12.5K | ﹤0.01% | 4803 |
|
|
2020
Q2 | $223K | Sell |
18,065
-900
| -5% | -$5.08K | ﹤0.01% | 4377 |
|
|
2020
Q1 | $54K | Buy |
18,965
+3,000
| +19% | +$15K | ﹤0.01% | 5116 |
|
|
2019
Q4 | $61K | Buy |
15,965
+1,045
| +7% | +$1.78K | ﹤0.01% | 5347 |
|
|
2019
Q3 | $18K | Buy |
14,920
+2,900
| +24% | +$3.6K | ﹤0.01% | 5543 |
|
|
2019
Q2 | $12K | Buy |
12,020
+2,230
| +23% | +$2.57K | ﹤0.01% | 5961 |
|
|
2019
Q1 | $16K | Sell |
9,790
-1,303
| -12% | -$1.64K | ﹤0.01% | 5757 |
|
|
2018
Q4 | $13K | Sell |
11,093
-629
| -5% | -$1.44K | ﹤0.01% | 5761 |
|
|
2018
Q3 | $43K | Buy |
11,722
+629
| +6% | +$1.99K | ﹤0.01% | 5310 |
|
|
2018
Q2 | $33K | Buy |
11,093
+2,209
| +25% | +$8.18K | ﹤0.01% | 5327 |
|
|
2018
Q1 | $35K | Buy |
8,884
+237
| +3% | +$1.04K | ﹤0.01% | 5222 |
|
|
2017
Q4 | $38K | Sell |
8,647
-2,437
| -22% | -$11.5K | ﹤0.01% | 5309 |
|
|
2017
Q3 | $61K | Buy |
11,084
+6,157
| +125% | +$37.9K | ﹤0.01% | 5307 |
|
|
2017
Q2 | $38K | Sell |
4,927
-228
| -4% | -$985 | ﹤0.01% | 5244 |
|
|
2017
Q1 | $19K | Buy |
5,155
+2,303
| +81% | +$11.4K | ﹤0.01% | 5649 |
|
|
2016
Q4 | $16K | Sell |
2,852
-837
| -23% | -$5.58K | ﹤0.01% | 5878 |
|
|
2016
Q3 | $29K | Sell |
3,689
-6,831
| -65% | -$51K | ﹤0.01% | 5394 |
|
|
2016
Q2 | $66K | Sell |
10,520
-6,000
| -36% | -$46.6K | ﹤0.01% | 4981 |
|
|
2016
Q1 | $136K | Buy |
16,520
+15,920
| +2,653% | +$150K | ﹤0.01% | 4601 |
|
|
2015
Q4 | $10K | Sell |
600
-300
| -33% | -$4.45K | ﹤0.01% | 5961 |
|
|
2015
Q3 | $10K | Buy |
+900
| New | +$19.6K | ﹤0.01% | 5879 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Royal Bank of Canada's IBRX Position: Q1 2026 in Review
Royal Bank of Canada increased its ImmunityBio (IBRX) stake by 1,732% in Q1 2026, buying an estimated $9.62M and bringing the position to 1,486,049 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1819.
Royal Bank of Canada first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Royal Bank of Canada held 1,486,049 shares of ImmunityBio worth $11.4M as of Q1 2026.
- Royal Bank of Canada bought 1,404,922 ImmunityBio shares in Q1 2026, an estimated $9.62M.
- ImmunityBio made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1819 holding.
- Royal Bank of Canada first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.